EML4 and non-small cell lung carcinoma: In a group of 29 NSCLC patients, EML4-ALK-rearrangements were detected in platelets and correlated with shorter PFS, whereas the serial monitoring of one patient revealed resistance to crizotinib prior to radiographic PD based on EML4-ALK-positive platelets [213].